A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 85,000 shares of CADL stock, worth $340,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,000
Previous 60,200 41.2%
Holding current value
$340,000
Previous $373,000 57.91%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.02 - $7.76 $507 - $783
101 New
101 $0
Q4 2023

Feb 14, 2024

SELL
$0.68 - $1.47 $10,404 - $22,491
-15,300 Reduced 47.59%
16,852 $24,000
Q3 2023

Nov 14, 2023

BUY
$0.91 - $1.3 $29,258 - $41,797
32,152 New
32,152 $29,000
Q1 2023

May 15, 2023

BUY
$1.35 - $2.72 $63,684 - $128,313
47,174 New
47,174 $63,000
Q3 2022

Nov 14, 2022

BUY
$3.05 - $4.08 $51,395 - $68,752
16,851 New
16,851 $53,000

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $116M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.